Novavax Remains a Risk-On Stock in a Risk-Off Market
NVAX stock is down 16% this week bringing its 12-month loss to over 88%. The company is struggling to meet revenue expectations from its Covid-19 vaccine candidate. Demand for boosters is not likely to change the math in the short-term. Novavax (NASDAQ: NVAX) was making news this week as its stock price has fallen nearly…